EIKN (NASDAQ:EIKN - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.
Other equities analysts have also recently issued research reports about the stock. Zacks Research raised shares of EIKN to a "hold" rating in a research note on Friday, February 27th. Wedbush began coverage on shares of EIKN in a report on Thursday, February 26th. They issued an "underperform" rating and a $7.00 price objective for the company. JPMorgan Chase & Co. started coverage on shares of EIKN in a research note on Monday, March 2nd. They set an "overweight" rating and a $29.00 price objective on the stock. Bank of America assumed coverage on EIKN in a report on Monday, March 2nd. They set a "buy" rating and a $34.00 target price on the stock. Finally, Morgan Stanley initiated coverage on EIKN in a research report on Monday, March 2nd. They issued an "overweight" rating and a $32.00 target price for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, EIKN currently has a consensus rating of "Moderate Buy" and an average price target of $25.60.
Get Our Latest Stock Analysis on EIKN
EIKN Price Performance
Shares of EIKN opened at $9.81 on Friday. EIKN has a one year low of $9.81 and a one year high of $17.40.
About EIKN
(
Get Free Report)
We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider EIKN, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EIKN wasn't on the list.
While EIKN currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A forward-looking investment report spotlighting the seven space companies best positioned to benefit from accelerating commercialization in 2026. It explores key industry trends, major growth catalysts, and the stocks shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
